
    
      1. To evaluate if weekly Docetaxel-Irinotecan,a potentially non-cross-resistant regimen,can
           prolong the overall survival (OS) or the duration of remission in those patients who
           have achieved CR or PR by P-HDFL regimen

        2. To evaluate the efficacy of weekly Docetaxel-Irinotecan combination as salvage regimen
           for those patients who have either failed to achieve remission or have recurred from
           P-HDFL chemotherapy

        3. To find out the optimal doses for docetaxel and irinotecan in a weekly dosing schedule
           for gastric cancer patients

        4. To evaluate the toxicities of weekly Docetaxel-Irinotecan regimen in inoperable gastric
           cancers
    
  